Palisade Bio (PALI) Stock Price, News & Analysis

Company Overview

Palisade Bio is a clinical-stage biopharmaceutical company developing therapies for gastrointestinal diseases, with a focus on oral treatments for inflammatory bowel conditions.

Its pipeline includes PALI-2108, an investigational, gut-targeted PDE4 inhibitor being developed for ulcerative colitis and fibrostenotic Crohn’s disease. The company has also developed LB1148, an investigational serine protease inhibitor studied for its potential to support bowel function and reduce complications after abdominal surgery.

Palisade Bio’s candidates are in clinical development and are not approved for commercial use.

Key Stats

• Today's Range: $1.11 to $1.19
• 50-Day Range: $1.12 to $2.20
• 52-Week Range: $1.08 to $2.86
• Volume: 2.96 million shs
• Average Volume: 3.96 million shs
• Market Capitalization: $203.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Buy

Palisade Bio Stock Analysis - MarketRank™

Palisade Bio scored higher than 50% of companies evaluated by MarketBeat, and ranked 557th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Buy

Consensus Rating

Palisade Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Palisade Bio has a consensus price target of $9.00, representing about 669.2% upside from its current price of $1.17.

Amount of Analyst Coverage

Palisade Bio has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Palisade Bio are expected to decrease in the coming year, from ($0.22) to ($0.28) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Palisade Bio is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Palisade Bio is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Palisade Bio has a P/B Ratio of 1.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

16.82% of the float of Palisade Bio has been sold short.

Short Interest Ratio / Days to Cover

Palisade Bio has a short interest ratio ("days to cover") of 7.76.

Change versus previous month

Short interest in Palisade Bio has recently decreased by 7.74%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Palisade Bio does not currently pay a dividend.

Dividend Growth

Palisade Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: -0.24

News Sentiment

Palisade Bio has a news sentiment score of -0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Palisade Bio this week, compared to 3 articles on an average week.

Search Interest

Only 9 people have searched for PALI on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.

MarketBeat Follows

11 people have added Palisade Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 450% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Palisade Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.07% of the stock of Palisade Bio is held by insiders.

Percentage Held by Institutions

11.79% of the stock of Palisade Bio is held by institutions.

Company Calendar

• Last Earnings: 11/10/2026
• Today: 11/11/2026
• Stifel 2026 Healthcare Conference 2026: 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:PALI
• CIK: 1357459
• Web: www.palisadebio.com
• Phone: (858) 704-4900
• Fax: N/A
• Employees: 14
• Year Founded: 2005

Price Target and Rating

• Average Price Target for Palisade Bio: $9.00
• High Price Target: $25.00
• Low Price Target: $5.00
• Potential Upside/Downside: +669.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.78 million
• Net Margins: N/A
• Pretax Margin: -6,388.20%
• Return on Equity: -34.63%
• Return on Assets: -33.19%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 24.26
• Quick Ratio: 24.26

Sales & Book Value

• Annual Sales: $250 thousand
• Price / Sales: 815.58
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.87 per share
• Price / Book: 1.34

Miscellaneous

• Outstanding Shares: 174,270,000
• Free Float: 174,149,000
• Market Cap: $203.90 million
• Optionable: Not Optionable
• Beta: 1.61